Send to

Choose Destination
J Infect Dis. 2019 Oct 3. pii: jiz508. doi: 10.1093/infdis/jiz508. [Epub ahead of print]

Long-term immunogenicity of Measles vaccine: an Italian retrospective cohort study.

Author information

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy.
Hygiene Department, Bari Policlinico General Hospital, Bari, Italy.



Levels of antibodies induced by the Measles virus containing vaccine have been shown to decline over time, but actually there is not a formal recommendation about the opportunity of testing immunized subjects (in particular, HCWs) to investigate the persistence of Measles IgG.


This study aims to evaluate the long-time immunogenicity of Measles vaccine in a sample of medical students and residents of the University of Bari who attended the Hygiene Department for the biological risk assessment (April 2014-June 2018).


2,000 immunized (2 doses of MMR vaccine) students and residents have been tested. 305/2,000 (15%) subjects didn't show protective anti-Measles IgG. This proportion was higher among vaccinated at ≤15 months (20%) than in vaccinated at 16-23 months (17%) and at ≥24 months (10%; p<0.0001). After an MMR vaccine booster dose, we noted a seroconversion of 74% of seronegative HCWs. The overall seroconversion rate after a second dose booster was of 93%. No serious adverse events were noted after the booster doses.


An important proportion of subjects immunized for Measles don't show a protective IgG titer in the 10 years after the vaccination. Our management strategy seems consistent with the purpose of evidencing immunological memory.


booster dose; duration of immunization; healthcare workers


Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center